Compare GSK plc (GSK) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Workiva Inc — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Workiva Inc trades at $73.25 (market cap $4.01B). The key difference: GSK plc is far larger — about 22.9× Workiva Inc's market cap, and GSK plc pays a 3.9% dividend while Workiva Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Workiva Inc for 21 Days on average.
| GSK | WK | |
|---|---|---|
Market Cap | $91.88B | $4.01B |
Volume | 7,730,529 | 1,301,708 |
Sector | Health | Technology |
52-Week High | $61.18 | $93.31 |
52-Week Low | $43.24 | $44.31 |
Typical Hold Time | 93 Days | 21 Days |
Enterprise Value | $111.88B | $3.99B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Workiva (WK) trades at $73.69, up 3.02% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $86.00. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue grew to $966 million in 2026, turning a net loss in 2025 into a $47 million profit, reflecting improved operational efficiency and strong gross margins of 80.21%.
The stock presents a growth opportunity driven by AI product innovations and positive analyst sentiment, but high valuation multiples (P/E of 87.73) and competitive pressures pose risks. Upside potential exists if earnings momentum continues, though investors should monitor execution against guidance and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
